HCW Biologics Inc HCWB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $4.65
- Day Range
- $4.45–4.78
- 52-Week Range
- $1.50–44.10
- Bid/Ask
- $4.36 / $4.70
- Shares Outstanding
- 1.60M
- Market Cap
- $7.27M
- Volume/Avg
- 30,753 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.24
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 35
- Website
- https://www.hcwbiologics.com
Valuation
|
Metric
|
HCWB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.87 |
Price/Sales | 0.24 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
HCWB
|
|---|---|
Quick Ratio | 0.07 |
Current Ratio | 0.09 |
Interest Coverage | −1.38 |
Quick Ratio
HCWB
Profitability
|
Metric
|
HCWB
|
|---|---|
Return on Assets (Normalized) | −1.08% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | 6.93% |
Return on Assets
HCWB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#%&kx&K | LOCK|^K>> | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@nh@?WM | LOCK|RZ#& | $70B | |||
| argenx SE ADR
ARGX
| LOCK|KC@S<<V | LOCK|&D^ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%qHw?T | LOCK|#n<P$ | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|v#p@h^ | LOCK|^F | $36B | |||
| Moderna Inc
MRNA
| LOCK|SB!N<V$ | LOCK|CY@ | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|d&>jXbJc | LOCK|rQ@K | $25B | |||
| Incyte Corp
INCY
| LOCK|&N@hjY | LOCK|W# | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|&^?hDl | LOCK|h^Q | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|MxFXKzX | LOCK|c%$ | $17B |
United States